# OnCo record nct02955940 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02955940/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02955940", "NCT02955940" ;
  schema:name "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib"@en ;
  schema:description "A phase 2 trial of Ruxolitinib, Capecitabine, Regorafenib in colorectal cancer, run by Incyte Corporation, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02955940/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02955940> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2016-11-30" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/regorafenib/> ;
  onco:companies <https://onco.cc/companies/incyte/> .